Trial Profile
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms DUO-O
- Sponsors AstraZeneca; Myriad Genetic Laboratories
- 24 Aug 2023 Planned primary completion date changed from 23 Jun 2023 to 28 Aug 2023.
- 06 Jun 2023 Primary endpoint has been met (Progression Free Survival (PFS) - in all non-tBRCA patients - intent-to-treat (ITT) population) , according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Primary endpoint has been met (Progression Free Survival (PFS) - in non-tBRCAm patients) , according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology